Bempedoic Acid

證據等級: L5

預測適應症: 10 個

Bempedoic Acid: From Hypercholesterolemia to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Bempedoic acid is an ATP-citrate lyase (ACLY) inhibitor used to lower LDL-cholesterol. TxGNN's top-ranked predictions (hyperthyroidism, thyroid hormone resistance, two cattle diseases, CMV infection) are flagged in the evidence pack itself as likely false positives or model noise with no supporting literature — one is even a data-pairing error citing a paper about an unrelated drug. The only prediction with real supporting evidence is Homozygous Familial Hypercholesterolemia (HoFH) (rank 6), backed by 1 real-world cohort study and 16 additional publications, with a coherent mechanistic rationale.

Quick Overview

Item	Content
Original Indication	Not available from Finland licensing data (drug not yet marketed); pharmacologically an LDL-C–lowering agent (ACLY inhibitor)
Predicted New Indication	Homozygous Familial Hypercholesterolemia (HoFH)
TxGNN Prediction Score	99.48% (rank 5650 of full candidate list)
Evidence Level	L3 (real-world cohort study)
Finland Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Note on TxGNN ranking: Ranks 1–5, 7, and 10 (hyperthyroidism, thyroid hormone receptor-β resistance, malignant catarrh, infectious bovine rhinotracheitis, CMV infection, hyperthyroxinemia, pregnancy-associated osteoporosis) all scored higher than HoFH but carry no supporting clinical or literature evidence — two are veterinary/cattle diseases, and the one literature hit (PMID 40549098) discusses a different drug (tiratricol) entirely. These are treated as model noise and excluded from further evaluation. Rank 6 (HoFH) is the only candidate with real, verifiable evidence and is the subject of this report.

Why is This Prediction Reasonable?

Bempedoic acid is an ATP-citrate lyase (ACLY) inhibitor that acts upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. It is a prodrug requiring liver-specific activation by ACSVL1, which limits off-target effects to hepatic tissue. By inhibiting ACLY, it reduces hepatic cholesterol synthesis and upregulates LDL receptor (LDLR) expression, producing an LDL-C-lowering effect that is additive to statins and PCSK9 inhibitors.

HoFH is caused by biallelic loss-of-function mutations in the LDLR gene, leading to extreme, treatment-resistant LDL-C elevations from birth. Because bempedoic acid's LDL-C-lowering mechanism partly depends on LDLR upregulation, its efficacy in HoFH is mechanistically plausible but genotype-dependent: patients with residual LDLR function ("receptor-defective") are expected to respond better than those with a complete null/null genotype, a pattern also seen with statins in this population.

This mechanistic overlap — both the original indication (general/heterozygous hypercholesterolemia) and the predicted indication (HoFH) converge on the same LDL-C-lowering pathway — is the basis for the TxGNN signal, and is now supported by an initial real-world cohort study (PMID 41274797) evaluating bempedoic acid specifically in HoFH patients.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41274797	2026	Cohort (Real-world)	Journal of Clinical Lipidology	Real-world evaluation of bempedoic acid efficacy and tolerability specifically in HoFH patients
41741298	2026	Expert Consensus	Journal of Clinical Lipidology	National Lipid Association update on FH management, reviewing current diagnostic and therapeutic advances
41694628	2026	Case Report/Review	Clinical Case Reports	Case of catastrophic HoFH progression after interrupted follow-up, illustrating consequences of inadequate LDL-C control
41106315	2025	Review	Experimental and Molecular Pathology	Reviews innovative therapies for HoFH, including LDLR-independent approaches
33766264	2021	Review	J Am Coll Cardiol (JACC Focus Seminar)	Discusses bempedoic acid alongside inclisiran and PCSK9 inhibitors as emerging LDL-C/ApoB-lowering therapies
37071085	2024	Review	Cardiology in Review	Positions bempedoic acid among add-on lipid-lowering options for familial hypercholesterolemia
35466160	2022	Review	J Atherosclerosis and Thrombosis	Reviews advancements in HoFH treatment, contextualizing non-statin options
29449335	2018	Preclinical	Arterioscler Thromb Vasc Biol	Bempedoic acid lowers LDL-C and attenuates atherosclerosis in LDLR+/- and LDLR-/- miniature pigs, a direct model of the HoFH mechanism
38576462	2024	Review	Am J Preventive Cardiology	Reviews the importance of sustained LDL-C lowering across the ASCVD risk continuum
32243228	2020	Review	Postgraduate Medicine	Reviews emerging LDL-C-lowering agents including bempedoic acid

Finland Market Information

Bempedoic acid is not currently marketed in Finland — no marketing authorizations are on record (total_licenses: 0).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Bempedoic acid's LDL-C-lowering mechanism (ACLY inhibition → LDLR upregulation) is directly relevant to HoFH pathophysiology, and an initial real-world cohort study now supports this use, but efficacy is expected to be genotype-dependent (limited in null/null LDLR patients) and no randomized controlled trial data yet exist specifically for HoFH.

To proceed, the following is needed:

TFDA/Finnish package insert (warnings, contraindications) — currently a blocking data gap
Confirmed original indication and approved labeling (drug not yet marketed in Finland)
Genotype-stratified efficacy data (receptor-defective vs. null/null) from the cited real-world cohort or future prospective trials
Drug-drug interaction data, particularly with statins and PCSK9 inhibitors commonly co-administered in HoFH
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.